Tumor Necrosis Factor Receptor Superfamily Member 10B, Pipeline Review, H2 2019 – Constitutes Close to 25 Molecules – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Tumor Necrosis Factor Receptor Superfamily Member 10B – Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Summary

Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) pipeline Target constitutes close to 25 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes. The latest report Tumor Necrosis Factor Receptor Superfamily Member 10B – Pipeline Review, H2 2019, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) – Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) or Death receptor 5 (DR5) is a protein encoded by TNFRSF10B. This receptor is activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL) and thus transduces cell death signal and induces cell apoptosis. It promotes the activation of NF-kappa-B. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 5, 11, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Reasons to buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Topics Covered:

• Introduction
• Report Coverage
• Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) – Overview
• Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) – Therapeutics Development
• Products under Development by Stage of Development
• Products under Development by Therapy Area
• Products under Development by Indication
• Products under Development by Companies
• Products under Development by Universities/Institutes
• Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) – Therapeutics Assessment
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) – Companies Involved in Therapeutics Development
• AbbVie Inc
• Apollo Therapeutics LLC
• AstraZeneca Plc
• Beijing Sinotau Pharmaceutical Technology Co Ltd
• Beijing Sunbio Biotech Co Ltd
• Biomirex Inc
• Boehringer Ingelheim International GmbH
• Chengdu Huachuang Biotechnology Co Ltd
• Clover Biopharmaceuticals
• D&D Pharmatech Co Ltd
• Daiichi Sankyo Co Ltd
• Galaxy Biotech LLC
• Genmab A/S
• i2 Pharmaceuticals Inc
• IGM Biosciences Inc
• Inhibrx Inc
• JN Biosciences LLC
• MacroGenics Inc
• Neonc Technologies Inc
• Obio Technology (Shanghai) Corp Ltd
• Polaris Pharmaceuticals Inc
• Shanghai Gebaide Biotechnology Co Ltd
• Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) – Drug Profiles
• ABBV-621 – Drug Profile
• AD-510 – Drug Profile
• BI-905711 – Drug Profile
• Bispecific Antibody to Agonize EPHB6 and DR5 for Triple-Negative Breast Cancer – Drug Profile
• CD19L-sTRAIL – Drug Profile
• CTB-006 – Drug Profile
• DS-8273 – Drug Profile
• dulanermin – Drug Profile
• Fusion Protein to Agonize TRAIL Receptor-2 for Oncology – Drug Profile
• GEN-1029 – Drug Profile
• HuG-4.2 – Drug Profile
• HuGOH-729S – Drug Profile
• INBRX-109 – Drug Profile
• MEDI-3039 – Drug Profile
• Monoclonal Antibodies to Agonize DR5 for Oncology – Drug Profile
• Monoclonal Antibody to Agonize DR5 for Hematological Tumor and Solid Tumor – Drug Profile
• Monoclonal Antibody to Agonize TRAILR2 for Oncology – Drug Profile
• NEO-214 – Drug Profile
• POL-30000 – Drug Profile
• Recombinant Protein for Oncology – Drug Profile
• Recombinant Protein to Agonize TNFRSF10A, TNFRSF10B, TNFRSF10C and TNFRSF10D for Oncology – Drug Profile
• SCB-313 – Drug Profile
• SL-231 – Drug Profile
• Small Molecules to Agonize DR4 and DR5 for Colorectal Cancer – Drug Profile
• TLY-012 – Drug Profile
• Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) – Dormant Products
• Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) – Discontinued Products
• Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) – Product Development Milestones

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/uigsx7

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900